When used in FeLV or FIV naturally infected cats, rHuIFN-α may improve the clinical status; increase the RBC counts; decrease the anemia; increase the neutrophil and lymphocyte counts, improving the immune response against the virus and secondary infections; and improve the CD4+/CD8+ ratio. This evidence concerns the gene CD8A and anemia.